Starting from the scientific work by the team of Toufic Renno and Isabelle Coste, TheraPPI Bioscience modifies protein interactions to offer treatments where current therapies fail. TheraPPI’s approach represents a paradigm shift in tackling cancer resistance and non-curable rare diseases. The first program leverages a dual mechanism with killing cancer cells and activating an anti-tumoral immune response.
Discover more about TheraPPI
Innovation
Today, most of the targeted therapies used to treat cancer suffer from excessive resistance, which reduces their effectiveness over time in patients. In response to this major societal challenge, Kairos Discovery intends to bring to the clinical stage new therapeutic solutions for potential applications in cancers that have become resistant to current therapies.
Based on the academic research of Alexandre Bancet and Isabelle Krimm, notably conducted at the Cancer Research Center of Lyon, the company is developing a “first-in-class” approach to block key cellular mechanisms in the survival and aggressiveness of solid tumors and hematological cancers.
Based on the academic research of Alexandre Bancet and Isabelle Krimm, notably conducted at the Cancer Research Center of Lyon, the company is developing a “first-in-class” approach to block key cellular mechanisms in the survival and aggressiveness of solid tumors and hematological cancers.
Founded in October 2019 by Prof. Stéphane Depil, MD, PhD, onco-hematologist at CLB, based on the research work from his academic lab, ErVaccine Technologies is a spin off from Centre Léon Bérard (CLB) / Cancer Research Center of Lyon (CRCL).
Currently at a preclinical stage of development, the company specializes in the development of next generation cancer vaccines, and cell therapies based on modified T lymphocytes, targeting new families of non-conventional tumor antigens such as those derived from endogenous retroviruses (identified and patented therapeutic targets).
StromaCare was structured around the research group “Stromal Immune Interactions in Cancer” (Dir A. Hennino) bringing together players in basic research from Cancer Research Center of Lyon and clinicians from the Centre Léon Bérard (Lyon Anti-Cancer Center – CLB).
StromaCare is dedicated to the development of innovative oncology drugs, based on modulation of stromal components, for the treatment of solid tumors. StromaCare will focus on the development of these innovative compounds from translational research to proof of concept in humans, which represents its specific know-how and area of expertise.
Resulting from the work of Toufic Renno’s research team, Tollys was built on the discovery that the activation of the TLR3 receptor leads to differential effects in cancer cells and normal and immune cells. Tollys used these unique properties to rationally design a family of TLR3 agonists, of which TL-532 is the lead-candidate.
Discover Tollys